NCAM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Expression of CD56 was increased 1.8-fold in patients On TKI in comparison with healthy controls (p < 0.01), whereas it was reduced 1.5- and 2.8-fold (p < 0.05) in patients with new CML diagnosis in comparison with healthy donors and patients On TKI, respectively (Figure 1A).